- Conditions
- Bioavailability
- Interventions
- PF-07321332/ritonavir
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Clinical trials in New Haven, Connecticut
This page shows live ClinicalTrials.gov search results for New Haven, Connecticut, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in New Haven
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PLN-74809, Placebo
- Drug
- Lead sponsor
- Pliant Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 7 more
- Conditions
- Healthy
- Interventions
- vepdegestrant, esomeprazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Major Depression
- Interventions
- Pharmacogenetic Test
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,944 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 24
- States / cities
- North Little Rock, Arkansas • Palo Alto, California • San Francisco, California + 21 more
- Conditions
- Left Ventricular Systolic Dysfunction
- Interventions
- AI-ECG
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Critical Limb Ischemia
- Interventions
- care as usual
- Other
- Lead sponsor
- Saint Luke's Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Cleveland, Ohio
- Conditions
- Circadian Rhythm Disorders
- Interventions
- Daytime Bright Light, Usual Light
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Hypertension
- Interventions
- Hydrochlorothiazide (HCTZ), Chlorthalidone (CTD)
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 65 Years and older
- Enrollment
- 20,723 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 64 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PRM-151 (Zinpentraxin Alfa)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Not listed
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Sacramento, California • San Diego, California + 37 more
- Conditions
- Post-Operative Atrial Fibrillation
- Interventions
- AGN-151607, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 19
- States / cities
- Stanford, California • New Haven, Connecticut • Washington D.C., District of Columbia + 16 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Gan & Lee Insulin Glargine Injection, Lantus®
- Biological
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 576 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Fresno, California • Newport Beach, California + 41 more
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- Ixabepilone, Bevacizumab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Baltimore, Maryland